Personal information

Other IDs

Scopus Author ID: 6603687162

Activities

Collapse all

Employment (1)

Université Paul Sabatier Toulouse III UFR PCA: Toulouse, Midi-Pyrénées, FR

2005 to present | PROFESSOR (PULMONARY MEDECINE)
Employment
Source: Self-asserted source
JULIEN MAZIERES

Education and qualifications (2)

Université Paul Sabatier Toulouse III UFR PCA: Toulouse, Midi-Pyrénées, FR

2000 to 2005 | PHD
Education
Source: Self-asserted source
JULIEN MAZIERES

Université Paul Sabatier Toulouse III UFR PCA: Toulouse, Midi-Pyrénées, FR

1994 to 2000 | MEDICAL STUDIES
Education
Source: Self-asserted source
JULIEN MAZIERES

Works (50 of 193)

Items per page:
Page 1 of 4

Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

Journal of Clinical Oncology
2024-10-10 | Journal article
DOI: 10.1200/JCO.24.00581
Contributors: Benjamin J. Solomon; Geoffrey Liu; Enriqueta Felip; Tony S.K. Mok; Ross A. Soo; Julien Mazieres; Alice T. Shaw; Filippo de Marinis; Yasushi Goto; Yi-Long Wu et al.
Source: check_circle
Crossref

A pragmatic guide for management of adverse events associated with lorlatinib

Lung Cancer
2024-05 | Journal article
DOI: 10.1016/j.lungcan.2024.107535
Contributors: Geoffrey Liu; Julien Mazieres; Jan Stratmann; Sai-Hong Ignatius Ou; Tony Mok; Mary Grizzard; Yasushi Goto; Enriqueta Felip; Benjamin J. Solomon; Todd M. Bauer
Source: check_circle
Crossref

Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials

Journal of Clinical Pharmacy and Therapeutics
2024-01 | Journal article
DOI: 10.1155/2024/5437090
Contributors: Constance Bordet; Vincent Dongay; Yoann Zelmat; Julien Mazieres; Fabien Despas; Samuel Silvestre
Source: check_circle
Crossref

Data from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

2023-11-01 | Preprint
DOI: 10.1158/2159-8290.c.6908464
Contributors: Tina Cascone; Gozde Kar; Jonathan D. Spicer; Rosario García-Campelo; Walter Weder; Davey B. Daniel; David R. Spigel; Maen Hussein; Julien Mazieres; Julio Oliveira et al.
Source: check_circle
Crossref

Data from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

2023-11-01 | Preprint
DOI: 10.1158/2159-8290.c.6908464.v1
Contributors: Tina Cascone; Gozde Kar; Jonathan D. Spicer; Rosario García-Campelo; Walter Weder; Davey B. Daniel; David R. Spigel; Maen Hussein; Julien Mazieres; Julio Oliveira et al.
Source: check_circle
Crossref

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

Cancer Discovery
2023-11-01 | Journal article
DOI: 10.1158/2159-8290.CD-23-0436
Contributors: Tina Cascone; Gozde Kar; Jonathan D. Spicer; Rosario García-Campelo; Walter Weder; Davey B. Daniel; David R. Spigel; Maen Hussein; Julien Mazieres; Julio Oliveira et al.
Source: check_circle
Crossref

Supplementary Appendix from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

2023-11-01 | Preprint
DOI: 10.1158/2159-8290.24473995
Contributors: Tina Cascone; Gozde Kar; Jonathan D. Spicer; Rosario García-Campelo; Walter Weder; Davey B. Daniel; David R. Spigel; Maen Hussein; Julien Mazieres; Julio Oliveira et al.
Source: check_circle
Crossref

Supplementary Appendix from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

2023-11-01 | Preprint
DOI: 10.1158/2159-8290.24473995.v1
Contributors: Tina Cascone; Gozde Kar; Jonathan D. Spicer; Rosario García-Campelo; Walter Weder; Davey B. Daniel; David R. Spigel; Maen Hussein; Julien Mazieres; Julio Oliveira et al.
Source: check_circle
Crossref

Supplementary Data - Supplementary Table 7 from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

2023-11-01 | Preprint
DOI: 10.1158/2159-8290.24473992.v1
Contributors: Tina Cascone; Gozde Kar; Jonathan D. Spicer; Rosario García-Campelo; Walter Weder; Davey B. Daniel; David R. Spigel; Maen Hussein; Julien Mazieres; Julio Oliveira et al.
Source: check_circle
Crossref

Supplementary Data - Supplementary Table 7 from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

2023-11-01 | Preprint
DOI: 10.1158/2159-8290.24473992
Contributors: Tina Cascone; Gozde Kar; Jonathan D. Spicer; Rosario García-Campelo; Walter Weder; Davey B. Daniel; David R. Spigel; Maen Hussein; Julien Mazieres; Julio Oliveira et al.
Source: check_circle
Crossref

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes

Clinical Lung Cancer
2023-09 | Journal article
DOI: 10.1016/j.cllc.2023.06.008
Contributors: Julien Mazieres; Helene Vioix; Boris M. Pfeiffer; Rhiannon I. Campden; Zhiyuan Chen; Bart Heeg; Alexis B. Cortot
Source: check_circle
Crossref

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Journal of Clinical Oncology
2023-04-10 | Journal article
DOI: 10.1200/JCO.22.01990
Contributors: Silvia Novello; Dariusz M. Kowalski; Alexander Luft; Mahmut Gümüş; David Vicente; Julien Mazières; Jeronimo Rodríguez-Cid; Ali Tafreshi; Ying Cheng; Ki Hyeong Lee et al.
Source: check_circle
Crossref

Data from Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <i>BRAF</i>-Mutant Metastatic Non–Small Cell Lung Cancer

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6530096
Contributors: Sandra Ortiz-Cuaran; Laura Mezquita; Aurélie Swalduz; Mihalea Aldea; Julien Mazieres; Camille Leonce; Cecile Jovelet; Anne Pradines; Virginie Avrillon; Washington R. Chumbi Flores et al.
Source: check_circle
Crossref

Data from Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <i>BRAF</i>-Mutant Metastatic Non–Small Cell Lung Cancer

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6530096.v1
Contributors: Sandra Ortiz-Cuaran; Laura Mezquita; Aurélie Swalduz; Mihalea Aldea; Julien Mazieres; Camille Leonce; Cecile Jovelet; Anne Pradines; Virginie Avrillon; Washington R. Chumbi Flores et al.
Source: check_circle
Crossref

Data from Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6528681
Contributors: Guillaume Eberst; Amélie Anota; Arnaud Scherpereel; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Hervé Léna et al.
Source: check_circle
Crossref

Data from Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6528681.v1
Contributors: Guillaume Eberst; Amélie Anota; Arnaud Scherpereel; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Hervé Léna et al.
Source: check_circle
Crossref

Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6531026
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6531026.v1
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Data from Ultra-sensitive <i>EGFR</i><sup>T790M</sup> Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring <i>EGFR</i><sup>del19</sup> Mutations and Treated with First-generation TKIs

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6527717
Contributors: Julie A. Vendrell; Julien Mazieres; Romain Senal; Isabelle Rouquette; Xavier Quantin; Jean-Louis Pujol; Benoit Roch; Abdelali Bouidioua; Sylvain Godreuil; Etienne Coyaud et al.
Source: check_circle
Crossref

Data from Ultra-sensitive <i>EGFR</i><sup>T790M</sup> Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring <i>EGFR</i><sup>del19</sup> Mutations and Treated with First-generation TKIs

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6527717.v1
Contributors: Julie A. Vendrell; Julien Mazieres; Romain Senal; Isabelle Rouquette; Xavier Quantin; Jean-Louis Pujol; Benoit Roch; Abdelali Bouidioua; Sylvain Godreuil; Etienne Coyaud et al.
Source: check_circle
Crossref

Supplementary Data 1 from Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22474086
Contributors: Guillaume Eberst; Amélie Anota; Arnaud Scherpereel; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Hervé Léna et al.
Source: check_circle
Crossref

Supplementary Data 1 from Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22474086.v1
Contributors: Guillaume Eberst; Amélie Anota; Arnaud Scherpereel; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Hervé Léna et al.
Source: check_circle
Crossref

Supplementary Data from Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <i>BRAF</i>-Mutant Metastatic Non–Small Cell Lung Cancer

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22478981
Contributors: Sandra Ortiz-Cuaran; Laura Mezquita; Aurélie Swalduz; Mihalea Aldea; Julien Mazieres; Camille Leonce; Cecile Jovelet; Anne Pradines; Virginie Avrillon; Washington R. Chumbi Flores et al.
Source: check_circle
Crossref

Supplementary Data from Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <i>BRAF</i>-Mutant Metastatic Non–Small Cell Lung Cancer

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22478981.v1
Contributors: Sandra Ortiz-Cuaran; Laura Mezquita; Aurélie Swalduz; Mihalea Aldea; Julien Mazieres; Camille Leonce; Cecile Jovelet; Anne Pradines; Virginie Avrillon; Washington R. Chumbi Flores et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482905
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482899
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482899.v1
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482896
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482896.v1
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482905.v1
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482902
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482902.v1
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482893
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482893.v1
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482890.v1
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482890
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482887
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482884
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482884.v1
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482881
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482881.v1
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482878
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482887.v1
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22482878.v1
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref

Supplementary Data from Ultra-sensitive <i>EGFR</i><sup>T790M</sup> Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring <i>EGFR</i><sup>del19</sup> Mutations and Treated with First-generation TKIs

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22470893
Contributors: Julie A. Vendrell; Julien Mazieres; Romain Senal; Isabelle Rouquette; Xavier Quantin; Jean-Louis Pujol; Benoit Roch; Abdelali Bouidioua; Sylvain Godreuil; Etienne Coyaud et al.
Source: check_circle
Crossref

Supplementary Data from Ultra-sensitive <i>EGFR</i><sup>T790M</sup> Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring <i>EGFR</i><sup>del19</sup> Mutations and Treated with First-generation TKIs

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22470893.v1
Contributors: Julie A. Vendrell; Julien Mazieres; Romain Senal; Isabelle Rouquette; Xavier Quantin; Jean-Louis Pujol; Benoit Roch; Abdelali Bouidioua; Sylvain Godreuil; Etienne Coyaud et al.
Source: check_circle
Crossref

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

Journal for ImmunoTherapy of Cancer
2022-10 | Journal article
DOI: 10.1136/jitc-2022-005636
Contributors: Marie Wislez; Julien Mazieres; Armelle Lavole; Gérard Zalcman; Olivier Carre; Thomas Egenod; Raffaele Caliandro; Catherine Dubos-Arvis; Gaelle Jeannin; Olivier Molinier et al.
Source: check_circle
Crossref

INSIGHT 2: a Phase II Study of Tepotinib Plus Osimertinib in MET -Amplified NSCLC and First-Line Osimertinib Resistance

Future Oncology
2022-03 | Journal article
DOI: 10.2217/fon-2021-1406
Contributors: Egbert F Smit; Christophe Dooms; Jo Raskin; Ernest Nadal; Lye M Tho; Xiuning Le; Julien Mazieres; How S Hin; Masahire Morise; Viola W Zhu et al.
Source: check_circle
Crossref

Mycobacteria–host interactions in human bronchiolar airway organoids

Molecular Microbiology
2022-03 | Journal article
DOI: 10.1111/mmi.14824
Contributors: Nino Iakobachvili; Stephen Adonai Leon‐Icaza; Kèvin Knoops; Norman Sachs; Serge Mazères; Roxane Simeone; Antonio Peixoto; Célia Bernard; Marlène Murris‐Espin; Julien Mazières et al.
Source: check_circle
Crossref

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Clinical Cancer Research
2022-03-15 | Journal article
DOI: 10.1158/1078-0432.CCR-21-2733
Contributors: Xiuning Le; Hiroshi Sakai; Enriqueta Felip; Remi Veillon; Marina Chiara Garassino; Jo Raskin; Alexis B. Cortot; Santiago Viteri; Julien Mazieres; Egbert F. Smit et al.
Source: check_circle
Crossref
Items per page:
Page 1 of 4

Peer review (6 reviews for 4 publications/grants)

Review activity for Cancer treatment reviews. (1)
Review activity for Nature medicine. (1)
Review activity for Respiratory medicine and research. (2)
Review activity for The Lancet regional health. (2)
How many people are using ORCID?